Home LiteratureArticle Details
PMID: 9560267 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator.

Felzien LK, Woffendin C, Hottiger MO, Subbramanian RA, Cohen EA, Nabel GJ

Abstract

The accessory protein, Vpr, is a virion-associated protein that is required for HIV-1 replication in macrophages and regulates viral gene expression in T cells. Vpr causes arrest of cell cycle progression at G2/M, presumably through its effect on cyclin B1.Cdc2 activity. Here, we show that the ability of Vpr to activate HIV transcription correlates with its ability to induce G2/M growth arrest, and this effect is mediated by the p300 transcriptional co-activator, which promotes cooperative interactions between the Rel A subunit of NF-kappaB and cyclin B1.Cdc2. Vpr cooperates with p300, which regulates NF-kappaB and the basal transcriptional machinery, to increase HIV gene expression. Similar effects are seen in the absence of Vpr with a kinase-deficient Cdc2, and overexpression of p300 increases levels of HIV Vpr+ replication. Taken together, these data suggest that p300, through its interactions with NF-kappaB, basal transcriptional components, and Cdks, is modulated by Vpr and regulates HIV replication. The regulation of p300 by Vpr provides a mechanism to enhance viral replication in proliferating cells after growth arrest by increasing viral transcription.

MeSH Terms
CDC2 Protein Kinase/physiology CREB-Binding Protein Cell Cycle Gene Expression Regulation, Viral Gene Products, vpr/genetics HIV-1/genetics Humans Jurkat Cells Nuclear Proteins/physiology Trans-Activators Transcription Factors/physiology Transcription, Genetic Virus Replication vpr Gene Products, Human Immunodeficiency Virus
Chemicals
Gene Products, vpr Nuclear Proteins Trans-Activators Transcription Factors vpr Gene Products, Human Immunodeficiency Virus CREB-Binding Protein CREBBP protein, human CDC2 Protein Kinase
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Felzien L K
Departments of Internal Medicine and Biological Chemistry, Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor, MI 48109-0650, USA.
Woffendin C
Hottiger M O
Subbramanian R A
Cohen E A
Nabel G J
References (56)
56 references, click to expand
  1. NF-kappa B-mediated activation of the human immunodeficiency virus enhancer: site of transcriptional initiation is independent of the TATA box.
    J Virol. 1989 Sep;63(9):4097-100 PMID: 2527315
  2. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.
    Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7311-5 PMID: 8041786
  3. The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV.
    Cell. 1988 Jun 3;53(5):827-36 PMID: 2836068
  4. HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor.
    Nature. 1988 Jun 23;333(6175):776-8 PMID: 2838755
  5. Cellular transcription factors and regulation of IL-2 receptor gene expression by HTLV-I tax gene product.
    Science. 1988 Jul 1;241(4861):89-92 PMID: 2838905
  6. Cellular targets for transformation by the adenovirus E1A proteins.
    Cell. 1989 Jan 13;56(1):67-75 PMID: 2521301
  7. Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B.
    Nature. 1989 May 4;339(6219):70-3 PMID: 2654643
  8. Identification of HIV-1 vpr product and function.
    J Acquir Immune Defic Syndr. 1990;3(1):11-8 PMID: 2136707
  9. Silencing of human immunodeficiency virus long terminal repeat expression by an adenovirus E1a mutant.
    Proc Natl Acad Sci U S A. 1990 Feb;87(4):1310-4 PMID: 2137611
  10. Analysis of E1A-mediated growth regulation functions: binding of the 300-kilodalton cellular product correlates with E1A enhancer repression function and DNA synthesis-inducing activity.
    J Virol. 1990 Sep;64(9):4421-7 PMID: 2143544
  11. Identification of specific adenovirus E1A N-terminal residues critical to the binding of cellular proteins and to the control of cell growth.
    J Virol. 1993 Jan;67(1):476-88 PMID: 8416379
  12. Induction of cell differentiation by human immunodeficiency virus 1 vpr.
    Cell. 1993 Feb 26;72(4):541-50 PMID: 8440020
  13. Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3).
    Mol Cell Biol. 1993 Mar;13(3):1315-22 PMID: 8441377
  14. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.
    J Virol. 1993 Dec;67(12):7229-37 PMID: 8230445
  15. Transcription factor AP-2 regulates human immunodeficiency virus type 1 gene expression.
    J Virol. 1994 Oct;68(10):6820-3 PMID: 8084021
  16. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection.
    J Virol. 1995 Feb;69(2):882-8 PMID: 7815556
  17. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.
    Virology. 1995 Feb 1;206(2):935-44 PMID: 7531918
  18. NF-kappa B: a lesson in family values.
    Cell. 1995 Feb 24;80(4):529-32 PMID: 7867060
  19. Regulation of human retroviral latency by the NF-kappa B/I kappa B family: inhibition of human immunodeficiency virus replication by I kappa B through a Rev-dependent mechanism.
    Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1480-4 PMID: 7878004
  20. Structure, regulation and function of NF-kappa B.
    Annu Rev Cell Biol. 1994;10:405-55 PMID: 7888182
  21. The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.
    J Virol. 1995 May;69(5):2759-64 PMID: 7707498
  22. Repression in vitro, by human adenovirus E1A protein domains, of basal or Tat-activated transcription of the human immunodeficiency virus type 1 long terminal repeat.
    J Virol. 1995 May;69(5):2907-11 PMID: 7707515
  23. Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300.
    Genes Dev. 1995 May 15;9(10):1188-98 PMID: 7758944
  24. Rel/NF-kappa B/I kappa B story.
    Adv Cancer Res. 1995;66:255-92 PMID: 7793317
  25. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle.
    J Virol. 1995 Oct;69(10):6304-13 PMID: 7666531
  26. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.
    J Virol. 1995 Nov;69(11):6705-11 PMID: 7474080
  27. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B.
    J Virol. 1995 Nov;69(11):6859-64 PMID: 7474100
  28. A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.
    J Virol. 1995 Nov;69(11):6873-9 PMID: 7474102
  29. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation.
    J Virol. 1995 Nov;69(11):7032-44 PMID: 7474123
  30. CBP-induced stimulation of c-Fos activity is abrogated by E1A.
    EMBO J. 1995 Oct 2;14(19):4758-62 PMID: 7588605
  31. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo.
    Nat Med. 1995 Oct;1(10):1052-6 PMID: 7489362
  32. Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr.
    J Virol. 1995 Dec;69(12):7909-16 PMID: 7494303
  33. Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro.
    Oncogene. 1995 Dec 21;11(12):2509-14 PMID: 8545107
  34. Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import.
    J Virol. 1996 Feb;70(2):1027-32 PMID: 8551560
  35. CBP as a transcriptional coactivator of c-Myb.
    Genes Dev. 1996 Mar 1;10(5):528-40 PMID: 8598284
  36. Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control.
    J Virol. 1996 Apr;70(4):2324-31 PMID: 8642659
  37. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors.
    Cell. 1996 May 3;85(3):403-14 PMID: 8616895
  38. Regulation of the c-fos promoter by the ternary complex factor Sap-1a and its coactivator CBP.
    Oncogene. 1996 May 2;12(9):1961-9 PMID: 8649857
  39. Human p300 protein is a coactivator for the transcription factor MyoD.
    J Biol Chem. 1996 Apr 12;271(15):9009-13 PMID: 8621548
  40. Interaction of the co-activator CBP with Myb proteins: effects on Myb-specific transactivation and on the cooperativity with NF-M.
    EMBO J. 1996 Jun 3;15(11):2771-80 PMID: 8654374
  41. The signal-dependent coactivator CBP is a nuclear target for pp90RSK.
    Cell. 1996 Aug 9;86(3):465-74 PMID: 8756728
  42. HIV-1, Vpr and the cell cycle.
    Curr Biol. 1996 Sep 1;6(9):1096-103 PMID: 8805364
  43. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha.
    Nature. 1996 Sep 26;383(6598):344-7 PMID: 8848048
  44. Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation.
    Genes Dev. 1996 Oct 1;10(19):2478-90 PMID: 8843199
  45. The transcriptional coactivators p300 and CBP are histone acetyltransferases.
    Cell. 1996 Nov 29;87(5):953-9 PMID: 8945521
  46. The CBP co-activator is a histone acetyltransferase.
    Nature. 1996 Dec 19-26;384(6610):641-3 PMID: 8967953
  47. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator.
    Science. 1997 Jan 24;275(5299):523-7 PMID: 8999795
  48. Distinct domains of adenovirus E1A interact with specific cellular factors to differentially modulate human immunodeficiency virus transcription.
    J Virol. 1997 Mar;71(3):2004-12 PMID: 9032332
  49. Synergistic activation of transcription by CBP and p53.
    Nature. 1997 Jun 19;387(6635):819-23 PMID: 9194564
  50. Binding and modulation of p53 by p300/CBP coactivators.
    Nature. 1997 Jun 19;387(6635):823-7 PMID: 9194565
  51. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B.
    Nat Med. 1997 Oct;3(10):1117-23 PMID: 9334723
  52. Distinct roles for cyclin-dependent kinases in cell cycle control.
    Science. 1993 Dec 24;262(5142):2050-4 PMID: 8266103
  53. Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles.
    J Virol. 1994 Mar;68(3):1926-34 PMID: 8107252
  54. Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate.
    Virology. 1994 May 1;200(2):623-31 PMID: 8178448
  55. Nuclear protein CBP is a coactivator for the transcription factor CREB.
    Nature. 1994 Jul 21;370(6486):223-6 PMID: 7913207
  56. An inducible transcription factor activates expression of human immunodeficiency virus in T cells.
    Nature. 1987 Apr 16-22;326(6114):711-3 PMID: 3031512
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
1998-04-28
Pages
5281-6
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC20252
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]